Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development

作     者：Jie Liang Xiao Zhao Jie Liang;Xiao Zhao

作者机构：CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety&CAS Center for Excellence in NanoscienceNational Center for Nanoscience and Technology of ChinaBeijing 100190China University of Chinese Academy of SciencesBeijing 100049China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2021年第18卷第2期

页      面：352-371页

核心收录：

学科分类：1002[医学-临床医学] 08[工学] 0805[工学-材料科学与工程（可授工学、理学学位）] 

基　　金：supported by the National Key R&D Program of China(Grant Nos.2018YFA0208900 and 2018YFE0205300) the Beijing Natural Science Foundation of China(Grant No.Z200020) the Beijing Nova Program(Grant No.Z201100006820031) the Taishan Scholars Program of Shandong Province(Grant No.ts20190987) the National Natural Science Foundation of China(Grant Nos.31800838,31820103004,31730032,and 31800799) the Key Research Project of Frontier Science of the Chinese Academy of Sciences(Grant No.QYZDJSSW-SLH022) the Innovation Research Group of National Natural Science Foundation(Grant No.11621505) the Hundred-Talent Program of the Chinese Academy of Sciences。 

主　　题：Nanomaterial-based delivery vehicles bioinformatic prediction neoantigen personalized vaccines tumor immunotherapy 

摘      要：Nanomaterial-based delivery vehicles such as lipid-based,polymer-based,inorganics-based,and bio-inspired vehicles often carry distinct and attractive advantages in the development of therapeutic cancer vaccines.Based on various delivery vehicles,specifically designed nanomaterials-based vaccines are highly advantageous in boosting therapeutic and prophylactic antitumor immunities.Specifically,therapeutic vaccines featuring unique properties have made major contributions to the enhancement of antigen immunogenicity,encapsulation efficiency,biocompatibility,and stability,as well as promoting antigen cross-presentation and specific CD8^(+)T cell responses.However,for clinical applications,tumor-associated antigen-derived vaccines could be an obstacle,involving immune tolerance and deficiency of tumor specificities,in achieving maximum therapeutic indices.However,when using bioinformatics predictions with emerging innovations of in silico tools,neoantigen-based therapeutic vaccines might become potent personalized vaccines for tumor treatments.In this review,we summarize the development of preclinical therapeutic cancer vaccines and the advancements of nanomaterial-based delivery vehicles for cancer immunotherapies,which provide the basis for a personalized vaccine delivery platform.Moreover,we review the existing challenges and future perspectives of nanomaterial-based personalized vaccines for novel tumor immunotherapies.